Mounting evidence of FKBP12 implication in neurodegeneration.
Alzheimer’s disease
FK506 binding protein
FKBP12
Parkinson’s disease
biomarker
detections
neurodegeneration
tau protein
α-synuclein
Journal
Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
29
6
2020
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
ppublish
Résumé
Intrinsically disordered proteins, such as tau or α-synuclein, have long been associated with a dysfunctional role in neurodegenerative diseases. In Alzheimer's and Parkinson's' diseases, these proteins, sharing a common chemical-physical pattern with alternating hydrophobic and hydrophilic domains rich in prolines, abnormally aggregate in tangles in the brain leading to progressive loss of neurons. In this review, we present an overview linking the studies on the implication of the peptidyl-prolyl isomerase domain of immunophilins, and notably FKBP12, to a variety of neurodegenerative diseases, focusing on the molecular origin of such a role. The involvement of FKBP12 dysregulation in the aberrant aggregation of disordered proteins pinpoints this protein as a possible therapeutic target and, at the same time, as a predictive biomarker for early diagnosis in neurodegeneration, calling for the development of reliable, fast and cost-effective detection methods in body fluids for community-based screening campaigns.
Identifiants
pubmed: 32594030
pii: NeuralRegenRes_2020_15_12_2195_284980
doi: 10.4103/1673-5374.284980
pmc: PMC7749462
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2195-2202Déclaration de conflit d'intérêts
None
Références
Oncol Lett. 2017 Apr;13(4):2811-2816
pubmed: 28454471
Protein Sci. 2007 Dec;16(12):2618-25
pubmed: 18029417
Oncogene. 2019 Mar;38(10):1688-1701
pubmed: 30348988
Clin Chim Acta. 2019 Aug;495:318-325
pubmed: 31051162
Parkinsonism Relat Disord. 2018 Apr;49:4-8
pubmed: 29409704
Neurosci Lett. 2009 Aug 7;459(2):96-9
pubmed: 19414059
J Neurochem. 2015 Apr;133(1):1-13
pubmed: 25628064
J Med Chem. 2013 Feb 14;56(3):1041-51
pubmed: 23301792
Curr Mol Pharmacol. 2015;9(1):48-65
pubmed: 25986568
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
J Proteome Res. 2007 Oct;6(10):3952-61
pubmed: 17877381
Curr Opin Pharmacol. 2011 Aug;11(4):365-71
pubmed: 21803654
Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1206-15
pubmed: 26884195
Expert Opin Ther Pat. 2013 Nov;23(11):1435-49
pubmed: 23957229
Int J Mol Med. 2019 Feb;43(2):868-878
pubmed: 30483787
BMC Cancer. 2019 Apr 11;19(1):351
pubmed: 30975104
Expert Opin Investig Drugs. 2000 Oct;9(10):2331-42
pubmed: 11060810
ACS Nano. 2012 Jul 24;6(7):5952-60
pubmed: 22695112
Angew Chem Int Ed Engl. 2020 Mar 27;59(14):5643-5646
pubmed: 31830361
N Engl J Med. 2013 Jul 25;369(4):341-50
pubmed: 23883379
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Feb 1;883-884:18-32
pubmed: 22197607
J Am Soc Mass Spectrom. 1995 Feb;6(2):85-90
pubmed: 24222070
Mov Disord. 2019 Sep;34(9):1354-1364
pubmed: 31361367
Anal Biochem. 2017 Nov 1;536:59-68
pubmed: 28803887
J Enzyme Inhib Med Chem. 2019 Dec;34(1):1711-1715
pubmed: 31547734
Neural Regen Res. 2020 Aug;15(8):1417-1420
pubmed: 31997800
Cancer Chemother Pharmacol. 2019 Oct;84(4):861-872
pubmed: 31428819
Int J Mol Sci. 2014 Jan 15;15(1):1040-67
pubmed: 24434619
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):9080-9085
pubmed: 28784767
FEBS J. 2019 Mar;286(6):1230-1239
pubmed: 30536857
BMC Dev Biol. 2018 Mar 27;18(1):7
pubmed: 29587629
Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):E11313-E11322
pubmed: 29229832
Small. 2018 Aug;14(35):e1801488
pubmed: 30066359
Sci Transl Med. 2019 Jan 23;11(476):
pubmed: 30674654
Trends Neurosci. 2004 Mar;27(3):129-34
pubmed: 15036877
Clin Chim Acta. 2019 Mar;490:222-228
pubmed: 30471248
FEBS Lett. 1998 Aug 7;432(3):202-6
pubmed: 9720925
Exp Neurol. 2005 Apr;192(2):244-50
pubmed: 15755542
Ann Transl Med. 2015 Apr;3(5):70
pubmed: 25992369
Autophagy. 2020 Jan;16(1):52-69
pubmed: 30898012
Brain Res. 2018 Feb 1;1680:39-45
pubmed: 29246765
Mol Neurobiol. 2011 Aug;44(1):13-27
pubmed: 21553017
J Neurosci. 1995 Apr;15(4):2985-94
pubmed: 7536825
Neural Regen Res. 2020 Mar;15(3):407-415
pubmed: 31571649
Brain. 2017 Oct 1;140(10):2722-2736
pubmed: 28969383
FASEB J. 2006 Mar;20(3):524-6
pubmed: 16410343
Proteomics. 2014 Dec;14(23-24):2731-41
pubmed: 25297486
Ann Clin Biochem. 2003 Jan;40(Pt 1):25-40
pubmed: 12542908
Cell Signal. 2017 Oct;38:97-105
pubmed: 28652145
Anal Chim Acta. 2015 Jul 16;884:90-6
pubmed: 26073814
Biochemistry. 2010 Nov 2;49(43):9345-52
pubmed: 20828147
Front Pharmacol. 2018 Dec 05;9:1425
pubmed: 30568592
Rev Neurol. 2018 Jun 1;66(11):377-386
pubmed: 29790571
Physiol Behav. 2002 Dec;77(4-5):463-8
pubmed: 12526984
Alzheimers Dement. 2014 Jan;10(1):115-31
pubmed: 23850333
Oxid Med Cell Longev. 2018 Jun 26;2018:1725191
pubmed: 30046369
Onco Targets Ther. 2019 Nov 01;12:9069-9076
pubmed: 31802914
Curr Med Chem. 2011;18(35):5380-97
pubmed: 22087831
Rev Neurosci. 2019 Jul 26;30(5):455-462
pubmed: 30471223
Mol Med Rep. 2018 Jan;17(1):763-770
pubmed: 29115621
Nature. 1989 Oct 26;341(6244):758-60
pubmed: 2477715
Mol Neurodegener. 2013 May 12;8:15
pubmed: 23663320
J Med Chem. 2016 Nov 10;59(21):9622-9644
pubmed: 27409354
Int J Mol Sci. 2017 Feb 18;18(2):
pubmed: 28218707
Respir Res. 2018 Apr 19;19(1):67
pubmed: 29673351
J Proteome Res. 2015 Nov 6;14(11):4486-501
pubmed: 26401960
Circulation. 2001 Mar 13;103(10):1396-402
pubmed: 11245643
Biophys J. 2013 Sep 3;105(5):1192-8
pubmed: 24010662
J Proteome Res. 2019 Aug 2;18(8):2987-2998
pubmed: 31274323
J Cell Biochem. 2019 Aug;120(8):13321-13329
pubmed: 30887568
PLoS One. 2012;7(2):e31956
pubmed: 22363773
Front Neurosci. 2018 Jan 30;12:25
pubmed: 29440986
Lancet Neurol. 2019 Jun;18(6):573-586
pubmed: 30981640
J Proteomics. 2015 Apr 24;119:90-9
pubmed: 25661039